Laboratorios Farmaceuticos ROVI SA
MAD:ROVI

Watchlist Manager
Laboratorios Farmaceuticos ROVI SA Logo
Laboratorios Farmaceuticos ROVI SA
MAD:ROVI
Watchlist
Price: 63 EUR 1.86% Market Closed
Market Cap: 3.2B EUR
Have any thoughts about
Laboratorios Farmaceuticos ROVI SA?
Write Note

Laboratorios Farmaceuticos ROVI SA
Cash from Financing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Laboratorios Farmaceuticos ROVI SA
Cash from Financing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Financing Activities CAGR 3Y CAGR 5Y CAGR 10Y
Laboratorios Farmaceuticos ROVI SA
MAD:ROVI
Cash from Financing Activities
-€104.8m
CAGR 3-Years
-43%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Almirall SA
MAD:ALM
Cash from Financing Activities
-€32.7m
CAGR 3-Years
N/A
CAGR 5-Years
12%
CAGR 10-Years
N/A
F
Faes Farma SA
MAD:FAE
Cash from Financing Activities
-€24.2m
CAGR 3-Years
0%
CAGR 5-Years
16%
CAGR 10-Years
N/A
Laboratorio Reig Jofre SA
MAD:RJF
Cash from Financing Activities
€7.2m
CAGR 3-Years
-20%
CAGR 5-Years
-26%
CAGR 10-Years
N/A
No Stocks Found

Laboratorios Farmaceuticos ROVI SA
Glance View

Market Cap
3.3B EUR
Industry
Pharmaceuticals

Laboratorios Farmaceúticos Rovi SA engages in the research, development, manufacture, and marketing of small molecule and specialty biologic drugs. The company is headquartered in Madrid, Madrid and currently employs 1,751 full-time employees. The company went IPO on 2007-10-26. The Company’s main activities include the development and commercialization, nationwide and abroad, of medicines and drugs. Its products are structured into three fields: Diagnostic, which offers contrast mediums for use in magnetic resonance, ultrasound and X-ray diagnostics; Prescription, which distributes medicines under such brands as Hibor, Osseor, Hepadren, Pneumovax-23, Glufan, Corlentor, Exxiv, Calcio y Vitamina D3 Rovi and Absorcol, among others; and Over The Counter (OTC), which comprises the Perspirex, Enerzona, Dentimelo and ColdPack brands. The firm owns such fully consolidated subsidiaries as Gineladius SL, Frosst Iberica SA, Rovi Contract Manufacturing SL and Bertex Pharma GmbH, among others.

ROVI Intrinsic Value
83.93 EUR
Undervaluation 25%
Intrinsic Value
Price

See Also

What is Laboratorios Farmaceuticos ROVI SA's Cash from Financing Activities?
Cash from Financing Activities
-104.8m EUR

Based on the financial report for Sep 30, 2024, Laboratorios Farmaceuticos ROVI SA's Cash from Financing Activities amounts to -104.8m EUR.

What is Laboratorios Farmaceuticos ROVI SA's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 3Y
-43%

Over the last year, the Cash from Financing Activities growth was -9%. The average annual Cash from Financing Activities growth rates for Laboratorios Farmaceuticos ROVI SA have been -43% over the past three years .

Back to Top